Study summary

In primary progressive MS, fenebrutinib matched the only approved drug

Fenebrutinib, progressive MS · 985 people (FENtrepid) · Reported November 2025

What was tested

Fenebrutinib pills against ocrelizumab infusions, the one approved treatment for primary progressive MS.

What they found

• Fenebrutinib was no worse than ocrelizumab at slowing disability over at least 120 weeks.
• Deaths occurred in 1.4% on fenebrutinib and 0.2% on ocrelizumab. Investigators judged them unrelated to treatment.

What it means

Could become the first pill for primary progressive MS. The difference in deaths will be examined closely by regulators.